Heart to Heart with Dr Michelle O'Donoghue

 
 
  • Is Lifelong LDL-C Lowering Within Reach?   Michelle O'Donoghue interviews Verve CEO and cardiologist Sekar Kathiresan about PCSK9 gene editing to lower LDL cholesterol and the findings of the heart-1 study.
  • PCI, the Antianginal 'Pill': ORBITA-2 in Detail   Michelle O'Donoghue interviews the sham PCI controlled trial investigators on the role of stents in the management of stable angina in light of both ORIBTA studies.
  • Is It Time for Cardiologists to Treat Obesity?   Cardiologists Michelle O'Donoghue and Nicholas Marston discuss the "game changer" trial at AHA showing that GLP-1 agonist semaglutide reduced CV events in patients with ASCVD and overweight/obesity.
  • Don't Fear POTS: Tips for Diagnosis and Treatment   Postural orthostatic tachycardia syndrome can challenge doctors. Cardiologists Pam Taub and Michelle O'Donoghue discuss how to diagnose and treat, and when to refer to a specialty clinic.
  • Is Complete Revascularization Now Compulsory?   Michelle O'Donoghue and interventional cardiologist Sahil Parikh discuss data presented at ESC on benefits for complete revascularization in both STEMI and NSTEMI that also extend to older patients.
  • Low-Dose Colchicine for ASCVD: Your Questions Answered   Cardiologist Michelle O'Donoghue asks Paul Ridker about the dos and don'ts for the anti-inflammatory drug colchicine in patients with atherosclerotic cardiovascular disease.
  • The Cardiac Stress Test You Can't Ignore   Pregnancy not only reveals a woman's future CV risk but can also cause changes at the endothelial level that increase that risk. Cardiologists Michelle O'Donoghue and Rachel Bond discuss the issues.
  • Is Bempedoic Acid the CLEAR Answer to Statin Intolerance?   Cardiologists Michelle O’Donoghue and Ann Marie Navar discuss the CLEAR Outcomes trial on Bempedoic acid in patients at high CV risk with statin intolerance and where this drug may fit in the lipid lowering arsenal.
  • AHA 2022 Does Lipoprotein(a) Play a Causal Role in ASCVD?   Michelle L. O'Donoghue, MD, MPH, and Stephen J. Nicholls, MBBS, PhD, discuss the evidence on lipoprotein(a) and its potential role in atherosclerosis and aortic stenosis.
  • AHA 2022 Did ISCHEMIA Change the Path to Cath in Stable CAD?   Michelle O'Donoghue and interventional cardiologists Rasha Al-Lamee, and Jacqueline Tamis-Holland discuss if the ISCHEMIA trial changed the management of patients with stable coronary artery disease.
  • ESC 2022 What's the Best Anticoagulation Strategy for COVID-19 Patients?   Drs Michelle O'Donoghue and David Berg discuss results from the COVID-PACT study, presented at the European Society of Cardiology, on anticoagulant therapy for hospitalized patients with COVID-19.
  • ESC 2022 Should Aspirin Be the Second-Line Antiplatelet in CAD?   From European Society of Cardiology 2022, Drs O'Donoghue and Valgimigli discuss the latest analysis suggesting that for single antiplatelet therapy in patients with CAD, P2Y12 inhibitors beat aspirin.
  • ACC 2022 Making Healthy (Plant-Based) Diets the Easy Choice   Drs Michelle O'Donoghue and Robert Ostfeld discuss plant-based nutrition and how to make it easier for us to choose healthy foods to improve our cardiovascular health.
  • ACC 2022 SuperWIN: Supermarket Partnership Improves DASH Diet Score   In a novel trial, DASH diet scores improved after participants were taught how to shop for healthier food, whether online or instore. Investigator Dylan Steen shares the details.
  • AHA 2021 Surgical Consult From AHA: Act Earlier in AS and TR?   Michelle O'Donoghue and Patrick O'Gara discuss early surgery in asymptomatic AS and concomitant TR repair in patients undergoing mitral valve surgery. Should either trial change practice?
  • ESC 2021 Is 1-Month DAPT Safe? Reconciling MASTER DAPT and STOPDAPT-2   Drs O'Donoghue and Valgimigli discuss abbreviated dual antiplatelet therapy data in high bleeding risk and acute coronary syndrome from studies presented at the 2021 European Society of Cardiology Congress.
  • ACC 2021 Does ADAPTABLE Inform Aspirin Dosing for Secondary Prevention?   Patient engagement, social media, and the internet all contributed to the unique design of the ADAPTABLE trial, but did it answer the question on the best dose of aspirin to use?
  • New Physician Moms Need More Resources and Less Guilt   Returning to practice after maternity leave prompted Michelle O'Donoghue to advocate for new moms in the healthcare workplace.
  • No Obstruction Shouldn't Mean No Diagnosis: HARP-MINOCA   A new study finds that multimodal imaging can reveal the cause of most MINOCA. Lead investigator Harmony Reynolds shares the details from her AHA presentation with Michelle O'Donoghue.
  • When It's Assumed That You're the Cleaner, Not a Cardiologist   Backstage at a cardiology conference, Michelle O'Donoghue was handed the dirty coffee mugs; the AV tech assumed she was the cleaner and not one of the late-breaking trial discussants.